Delving into the Latest Updates on Somatostatin(BCN Peptides SA) with Synapse

Overview

Basic Info

Drug Type

Synthetic peptide

Synonyms

Somatostatin

Target

SSTR1 x SSTR2 x SSTR3 x SSTR4 x SSTR5

Action

agonists

Mechanism

SSTR1 agonists(Somatostatin receptor 1 agonists), SSTR2 agonists(Somatostatin receptor 2 agonists), SSTR3 agonists(Somatostatin receptor 3 agonists)

+ [2]

Therapeutic Areas

Cardiovascular DiseasesEndocrinology and Metabolic DiseaseEye Diseases

Active Indication-

Inactive Indication

Diabetic Retinopathy

Originator Organization

BCN Peptides SA

Active Organization-

Inactive Organization

BCN Peptides SA

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC76H104N18O19S2

InChIKeyNHXLMOGPVYXJNR-ATOGVRKGSA-N

CAS Registry38916-34-6

In a broader scenario, the forced degradation studies provided by the ICH guidelines for Q1A, Q1B, and Q2B degradation studies allow to know the CQA of the mol. used as a drug product, to determine the appropriate anal. methods, excipients, and storage conditions ensuring the quality of the drug, its efficacy, and patient safety.In this study, we focused our attention on understanding how oxidative stress is performed by H₂O₂-impacted small synthetic peptides that do not contain residues susceptible to oxidation such as methionine.Among the amino acids susceptible to oxidation, methionine is the most reactive and depending on the structure of the protein where it is exposed, it tends to oxidize by converting into methionine sulfone or methionine sulfoxide by oxidation of its sulfur atom.Scouting experiments obtained by forced oxidative stress conditions are presented on two small synthetic peptides that do not contain any methionine residues spiked with different amounts of H₂O₂, and they are analyzed by LC-MS/MS.Less frequent oxidation products than those commonly observed on proteins/peptides-containing methionine have been characterized on both peptides.The study demonstrated that somatostatin, by means of one residue of tryptophan on the mol., can generate traces of several oxidized products detected by UPLC-MS.Furthermore, even at a negligible level, oxidation on tyrosine and proline in cetrorelix that does not contain methionine nor tryptophan has been detected by UHPLC-MS/MS.Identification and quantification of oxidized species were achieved by high-resolution MS and MS/MS experimentsThus, FDSs undoubtedly aid the evaluation of the CQAs as an important component of the characterization package as recommended by HAs and ICH, facilitating the understanding of unforeseen features of the studied mol. used as drugs.

05 Aug 2022·The Journal of Organic Chemistry

2-Methoxy-4-methylsulfinylbenzyl Alcohol as a Safety-Catch Linker for the Fmoc/tBu Solid-Phase Peptide Synthesis Strategy

Article

Author: Nandhini, K. P. ; Albericio, Fernando ; de la Torre, Beatriz G.

Fmoc and Boc group are the two main groups used to protect the α-amino function in Solid-Phase Peptide Synthesis (SPPS). In this regard, the use of the Mmsb linker allows the combination of these two groups. Peptide-O-Mmsb-Resin is stable to the piperidine and trifluoroacetic acid (TFA) treatment used to remove Fmoc and Boc, respectively. The peptide is detached in a two-step protocol, namely reduction of the sulfoxide to the sulfide with Me₃SiCl and Ph₃P, and then treatment with TFA. The advantage of this strategy has been demonstrated by the following: preparation of peptide with no diketopiperazine formation in sequences prone to this side reaction; on-resin cyclization without the concourse of common organic reagents such as Pd(0) but of difficult use in a biological laboratory; and on-resin disulfide formation in a total side-chain unprotected peptide. The use of Mmsb linker together with Msib (4-(methylsulfinyl)benzyl) and Msbh (4,4'-bis(methylsulfinyl)benzhydryl) described in the accompanying manuscript add a fourth dimension to the SPPS protecting group scheme.

01 Jul 2022·Food Research International

The combined effect of protein hydrolysis and Lactobacillus plantarum fermentation on antioxidant activity and metabolomic profiles of quinoa beverage

Article

Author: Meng, Fan-Bing ; Wang, Meng ; Liu, Da-Yu ; Zou, Long-Hua ; Li, Jia-Jia ; Li, Yun-Cheng ; Chen, Wei-Jun ; Zhou, Li

Lactic acid bacteria fermentation is a commonly applied technique to produce nutritional, functional, and organoleptic enhanced foods. In the present study, protein hydrolysis and Lactobacillus plantarum fermentation were coupled to develop quinoa beverages. Protein hydrolysis effectively promoted the growth and fermentation of L. plantarum. Fermentation alone did not significantly improve antioxidant activity, but the combined use of protein hydrolysis and L. plantarum fermentation significantly improved the antioxidant activity of the quinoa beverage. Nontargeted metabolomics based on UHPLC-Q Exactive HF-X/MS and multivariate statistical analysis were performed to reveal the metabolite profile alterations of the quinoa beverage by different processing methods. A total of 756 metabolites were identified and annotated, which could be categorized into 12 different classes. The significant differentially abundant metabolites were mainly involved in primary metabolite metabolism and secondary metabolite biosynthesis. Many of these metabolites were proven to be vitally important to the function and taste formation of the quinoa beverage. Most importantly, the coupled use of protein hydrolysis and L. plantarum fermentation significantly increased some functional ingredients compared with protein hydrolysis and L. plantarum fermentation alone. The above results indicate that protein hydrolysis coupled with L. plantarum fermentation is an effective strategy to develop functional quinoa beverages.

100 Deals associated with Somatostatin(BCN Peptides SA)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D07431	Somatostatin(BCN Peptides SA)	H01CB01	DB09099

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetic Retinopathy	Phase 3	Germany	BCN Peptides SA	01 Feb 2013
Diabetic Retinopathy	Phase 3	Denmark	BCN Peptides SA	01 Feb 2013
Diabetic Retinopathy	Phase 3	United Kingdom	BCN Peptides SA	01 Feb 2013
Diabetic Retinopathy	Phase 3	Italy	BCN Peptides SA	01 Feb 2013
Diabetic Retinopathy	Phase 3	France	BCN Peptides SA	01 Feb 2013
Diabetic Retinopathy	Phase 3	Portugal	BCN Peptides SA	01 Feb 2013
Diabetic Retinopathy	Phase 3	Spain	BCN Peptides SA	01 Feb 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.


No Data

Somatostatin(BCN Peptides SA)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation